(NASDAQ: ELDN) Eledon Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.18%.
Eledon Pharmaceuticals's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast ELDN's revenue for 2028 to be $1,041,942,885, with the lowest ELDN revenue forecast at $1,041,942,885, and the highest ELDN revenue forecast at $1,041,942,885. On average, 1 Wall Street analysts forecast ELDN's revenue for 2029 to be $6,527,113,475, with the lowest ELDN revenue forecast at $6,527,113,475, and the highest ELDN revenue forecast at $6,527,113,475.
In 2030, ELDN is forecast to generate $11,557,182,575 in revenue, with the lowest revenue forecast at $11,557,182,575 and the highest revenue forecast at $11,557,182,575.